Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesemCart for Knee Cartilage Damage
NCT06981741Phase 2Recruiting
- Sponsor
- BIONCaRT
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MesemCart in chondropathy, sponsored by BIONCaRT. Primary endpoint: Serious Adverse Events at 24 months. Started Nov 2025; status: recruiting.
02
Drugs
MesemCart
03
Conditions
chondropathy
Beyond the preview
Go deeper on NCT06981741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06981741.